Evidence map›Paper›PMID 34422956›Full record

ArticleAnnals of translational medicine2021

Characterization of comprehensive dynamic epigenetic changes during human primary Sjögren's syndrome progression.

Ningning Cao, Huan Shi, Chan Chen, Lisong Xie, Zhijun Wang, Lingyan Zheng, Chuangqi Yu

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 5 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ningning CaoDepartment of Oral and Maxillofacial Surgery, College of Stomatology, the Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Huan ShiDepartment of Oral and Maxillofacial Surgery, College of Stomatology, the Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Chan ChenDepartment of Oral and Maxillofacial Surgery, College of Stomatology, the Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Lisong XieDepartment of Oral and Maxillofacial Surgery, College of Stomatology, the Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Zhijun WangDepartment of Oral and Maxillofacial Surgery, College of Stomatology, the Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Lingyan ZhengDepartment of Oral and Maxillofacial Surgery, College of Stomatology, the Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Chuangqi YuDepartment of Oral and Maxillofacial Surgery, College of Stomatology, the Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China.
Shanghai Ninth People's Hospital · CNNational Clinical Research Center for Digestive Diseases · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by reduced exocrine gland (principally the salivary and lacrimal glands) activity caused by chronic lymphocytic infiltration. Although pSS has been closely associated with an increased risk of mucosa-associated lymphoid tissue (MALT) lymphoma, the dynamic epigenetic changes in the gland cells that accompany the pathogenesis are not entirely understood.

methodsIn this study, we harvested tissue samples from the labial gland with (LG_pSS) or without pSS (LG_NC) before MALT development, as well as the parotid gland with tumor tissues (PG_MALT) and paracancerous tissues (PG_NC) of two pSS patients with MALT lymphoma, and conducted RNA-seq and ChIP-seq for tri-methylated histone 3 lysine 4, 9, 27, 36, and 79 (H3K4/9/27/36/79me3).

resultsTranscriptome landscapes indicated two outcomes of pSS progression with or without MALT lymphoma represented by distinct populations of differentially expressed genes and their functions. Furthermore, the epigenetic atlas of genome-wide H3K4/9/27/36/79me3 was in different stages for various samples, indicating that the variance of H3K4me3 was the earliest event, followed by selective alterations of H3K9/27/36/79me3. These four epigenetic modifications determine the final outcome of pSS progression.

conclusionsOur results not only advance the understanding of the dynamics of pSS progression and highlight the importance of epigenetic alterations in regulating transcription during this pathological process, but also identify potential therapeutic targets for pSS treatment and lymphoma intervention.

Indexed as

epigenetic regulationmucosa-associated lymphoid tissue lymphoma (MALT lymphoma)Primary Sjögren’s syndrome (pSS)

Identifiers

PMID34422956
PMCPMC8339825
OpenAlexW3174364674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.